Eucomed challenges "irrational" national decisions:
This article was originally published in Clinica
Six issues that have been identified as priorities by the Eucomed Legal Issues Group for 2005 include challenging irrational national reimbursement decisions as well as continuing scrutiny and understanding of national procurement practices. These reflect the mounting obstacles that industry still faces despite regulatory convergence. The other four issues are: late payments and what can be learnt from the Spanish and Italian approaches; new technologies - the need for appropriate regulatory mechanisms to avoid the inevitable drift towards inappropriate and expensive pharma-based systems; strategic future of regulation - reform of the Medical Devices Directive and related legislation; and analysis of the implications of EU horizontal measures.
You may also be interested in...
Medical supplies manufacturers can collaborate to address the novel coronavirus pandemic without violating antitrust law, the US Department of Justice has said.
The submission of more trial data from Roche has prompted the US FDA to extend by three months its decision on whether to approve risdiplam for spinal muscular atrophy.
A temporary framework has been adopted by the European Commission that will allow companies and associations to co-ordinate efforts to tackle the coronavirus pandemic without raising competition concerns. The move has been welcomed by the European off-patent industry.